This page in English

Galina Selivanova

Professor

Besöksadress : Nobels Väg 16 171 77 Stockholm
Postadress : Institutionen för mikrobiologi, tumör- och cellbiologi (MTC), C1, Galina Selivanova grupp, Box 280 171 77 Stockholm
Leveransadress : Nobels Väg 16 171 77 Stockholm

Publikationer

Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka-pankau J, Selivanova G
Journal of internal medicine 2015;277(2):248-59

The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death
Xu J, Eriksson Se, Cebula M, Sandalova T, Hedström E, Pader I, et al
Cell death & disease 2015;6():e1616-

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors
Dickinson Er, Jurneczko E, Nicholson J, Hupp Tr, Zawacka-pankau J, Selivanova G, et al
Frontiers in molecular biosciences 2015;2():39-

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis
Li H, Zhang Y, Ströse A, Tedesco D, Gurova K, Selivanova G
Cell death and differentiation 2014;21(9):1493-502

Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53
Ireno Ic, Wiehe Rs, Stahl Ai, Hampp S, Aydin S, Troester Ma, et al
Carcinogenesis 2014;35(10):2273-82

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
Shi Y, Nikulenkov F, Zawacka-pankau J, Li H, Gabdoulline R, Xu J, et al
Cell death and differentiation 2014;21(4):612-23

Wild type p53 reactivation: from lab bench to clinic
Selivanova G
FEBS letters 2014;588(16):2628-38

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
Peng X, Zhang Mq, Conserva F, Hosny G, Selivanova G, Bykov Vj, et al
Cell death & disease 2013;4():e881-

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro
Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(18):5092-103

A novel facet of tumor suppression by p53 Induction of tumor immunogenicity
Li H, Lakshmikanth T, Carbone E, Selivanova G
ONCOIMMUNOLOGY 2012;1(4):541-543

Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis
Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M, et al
Cell death and differentiation 2012;19(12):1992-2002

Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo
Smith Sd, Enge M, Bao W, Thullberg M, Costa Td, Olofsson H, et al
The Journal of biological chemistry 2012;287(35):29336-47

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX
Spinnler C, Hedstrom E, Li H, De Lange J, Nikulenkov F, Teunisse Afas, et al
CELL DEATH AND DIFFERENTIATION 2011;18(11):1736-45

Inhibition of Glycolytic Enzymes Mediated by Pharmacologically Activated p53 TARGETING WARBURG EFFECT TO FIGHT CANCER
Zawacka-pankau J, Grinkevich Vv, Huenten S, Nikulenkov F, Gluch A, Li H, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2011;286(48):41600-15

Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, et al
CELL CYCLE 2011;10(19):3346-58

PRIMA-1(Met)/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53
Zandi R, Selivanova G, Christensen Cl, Gerds Ta, Willumsen Bm, Poulsen Hs
CLINICAL CANCER RESEARCH 2011;17(9):2830-41

PRIMA-1(Met)/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo
Bao Wj, Chen M, Zhao X, Kumar R, Spinnler C, Thullberg M, et al
CELL CYCLE 2011;10(2):301-7

Rescue of p53 Function by Small-Molecule RITA in Cervical Carcinoma by Blocking E6-Mediated Degradation
Zhao Cy, Szekely L, Bao Wj, Selivanova G
CANCER RESEARCH 2010;70(8):3372-81

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao Cy, Grinkevich Vv, Nikulenkov F, Bao Wj, Selivanova G
CELL CYCLE 2010;9(9):1847-55

Therapeutic targeting of p53 by small molecules
Selivanova G
SEMINARS IN CANCER BIOLOGY 2010;20(1):46-56

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
Grinkevich Vv, Nikulenkov F, Shi Y, Enge M, Bao Wj, Maljukova A, et al
CANCER CELL 2009;15(5):441-53

HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA
Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, et al
CANCER RESEARCH 2009;69(15):6241-8

Identification of tumour-suppressor-gene candidates in small cell lung cancer, which combined with a p53 reactivating molecule, can be used for cancer gene therapy
Zandi R, Selivanova G, Willumsen Bm, Poulsen Hs
JOURNAL OF THORACIC ONCOLOGY 2009;4(9):S592-S593

Integrins and Mutant p53 on the Road to Metastasis
Selivanova G, Ivaska J
CELL 2009;139(7):1220-2

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53
Enge M, Bao W, Hedstrom E, Jackson Sp, Moumen A, Selivanova G
CANCER CELL 2009;15(3):171-83

p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA
Hedstrom E, Eriksson S, Zawacka-pankau J, Arner Esj, Selivanova G
CELL CYCLE 2009;8(21):3584-91

Tumor-specific induction of apoptosis by a p53-reactivating compound
Hedstrom E, Issaeva N, Enge M, Selivanova G
EXPERIMENTAL CELL RESEARCH 2009;315(3):451-61

Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H, Selivanova G, Lehmann S, Mollgard L, Bengtzen S, Concha H, et al
BRITISH JOURNAL OF HAEMATOLOGY 2008;141(4):445-53

The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances
Zawacka-pankau J, Krachulec J, Grulkowski I, Bielawski Kp, Selivanova G
TOXICOLOGY AND APPLIED PHARMACOLOGY 2008;232(3):487-97

Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis
Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman Kg
CELL DEATH AND DIFFERENTIATION 2007;14(3):411-21

Kaposi's sarcoma herpesvirus load in biopsies of cutaneous and oral Kaposi's sarcoma lesions
Pak F, Mwakigonja Ar, Kokhaei P, Hosseinzadeh N, Pyakurel P, Kaaya E, et al
EUROPEAN JOURNAL OF CANCER 2007;43(12):1877-82

Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner
Zawacka-pankau J, Issaeva N, Hossain S, Pramanik A, Selivanova G, Podhajska Aj
JOURNAL OF BIOLOGICAL CHEMISTRY 2007;282(4):2466-72

Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova G, Wiman Kg
ONCOGENE 2007;26(15):2243-54

HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53
Hallgren O, Gustafsson L, Irjala H, Selivanova G, Orrenius S, Svanborg C
APOPTOSIS 2006;11(2):221-33

Identifying and charactering novel p53 regulated genes for potential anticancer therapy
Liu T, Laurell C, Selivanova G, Lundeberg J, Nilson P, Wiman Kg
ACTA PHARMACOLOGICA SINICA 2006;:412-413

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G, et al
BRITISH JOURNAL OF HAEMATOLOGY 2006;132(2):230-6

The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity
Okorokov Al, Sherman Mb, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, et al
EMBO JOURNAL 2006;25(21):5191-200

915 MHz microwaves and 50 Hz magnetic field affect chromatin conformation and 53BP1 foci in human lymphocytes from hypersensitive and healthy persons
Belyaev Iy, Hillert L, Protopopova M, Tamm C, Malmgren Log, Persson Brr, et al
BIOELECTROMAGNETICS 2005;26(3):173-84

Dose-response for radiation-induced apoptosis, residual 53BP1 foci and DNA-loop relaxation in human lymphocytes
Torudd J, Protopopova M, Sarimov R, Nygren J, Eriksson S, Markova E, et al
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 2005;81(2):125-38

HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry
Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah Aa, Selivanova G, et al
JOURNAL OF CUTANEOUS PATHOLOGY 2005;32(1):21-7

Mutant p53 reactivation as a novel strategy for cancer therapy
Wiman Kg, Stridh H, Zache N, Rokaeus N, Issaeva N, Hammarsund M, et al
ANNALS OF ONCOLOGY 2005;:23-24

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro - Reply
Grinkevich V, Issaeva N, Hossain S, Pramanik A, Selivanova G
NATURE MEDICINE 2005;11(11):1136-1137

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis
Bykov Vjn, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, et al
ONCOGENE 2005;24(21):3484-91

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
Bykov Vjn, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2005;280(34):30384-91

RITA activates p53 function in chronic lymphocytic leukaemia cells and induces apoptosis.
Nahi H, Merup M, Mollgard L, Selivanova G, Paul C
BLOOD 2005;106(11):472B-472B

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman Kg, et al
BRITISH JOURNAL OF HAEMATOLOGY 2004;127(3):285-91

p53: Fighting cancer
Selivanova G
CURRENT CANCER DRUG TARGETS 2004;4(5):385-402

Rescue of the p53 tumor suppressor by a rationally designed molecule
Selivanova G, Fersht A
Discovery medicine 2004;4(20):28-30

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef Lggc, Masucci M, et al
NATURE MEDICINE 2004;10(12):1321-8

Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain
Protopopova M, Selivanova G
Cell cycle (Georgetown, Tex.) 2003;2(6):592-5

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva N, Friedler A, Bozko P, Wiman Kg, Fersht Ar, Selivanova G
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003;100(23):13303-7

Small molecules that reactivate mutant p53
Bykov Vjn, Selivanova G, Wiman Kg
EUROPEAN JOURNAL OF CANCER 2003;39(13):1828-34

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin Tm, Bykov Vjn, Freund Smv, Selivanova G, Wiman Kg, Fersht Ar
ONCOGENE 2002;21(14):2119-29

Distinct p53 domains recognize different type of lesions
Protopopova M, Selivanova G
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 2002;11(10):1227S-1228S

Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2-and HPV-E6-induced proteolysis
Heessen S, Leonchiks A, Issaeva N, Sharipo A, Selivanova G, Masucci Mg, et al
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2002;99(3):1532-7

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
Bykov Vjn, Issaeva N, Selivanova G, Wiman Kg
CARCINOGENESIS 2002;23(12):2011-8

p53 induction as an indicator of DNA damage
Selivanova G
Methods in molecular biology (Clifton, N.J.) 2002;203():279-88

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov Vjn, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al
NATURE MEDICINE 2002;8(3):282-8

Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway
Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, Bartek J
ONCOGENE 2001;20(39):5503-10

Inactivation of Myc-induced p53-dependent apoptosis in human tumors
Henriksson M, Selivanova G, Lindstrom M, Wiman Kg
APOPTOSIS 2001;6(1-2):133-7

Mutant p53: the loaded gun
Selivanova G
Current opinion in investigational drugs (London, England : 2000) 2001;2(8):1136-41

Restoration of the tumor suppressor function of mutant p53 by a low molecular weight compound.
Bykov Vj, Issaeva N, Shilov A, Bergman J, Selivanova G, Wiman Kg
CLINICAL CANCER RESEARCH 2001;7(11):3749S-3749S

Restoration of transcriptional transactivation function of mutant p53 by small molecules.
Issaeva N, Shilov A, Bykov V, Wiman K, Selivanova G
CLINICAL CANCER RESEARCH 2001;7(11):3792S-3792S

Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein - Functional consequences of their interaction
Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, et al
JOURNAL OF BIOLOGICAL CHEMISTRY 2001;276(25):22699-708

Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
Xu Dw, Wang Q, Gruber A, Bjorkholm M, Chen Zg, Zaid A, et al
ONCOGENE 2000;19(45):5123-33

p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core
Zotchev Sb, Protopopova M, Selivanova G
NUCLEIC ACIDS RESEARCH 2000;28(20):4005-12

p53-induced apoptosis as a safeguard against cancer
Asker C, Wiman Kg, Selivanova G
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1999;265(1):1-6

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain
Selivanova G, Ryabchenko L, Jansson E, Iotsova V, Wiman Kg
MOLECULAR AND CELLULAR BIOLOGY 1999;19(5):3395-402

Reactivation of mutant p53: a new strategy for cancer therapy
Selivanova G, Kawasaki T, Ryabchenko L, Wiman Kg
SEMINARS IN CANCER BIOLOGY 1998;8(5):369-78

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al
NATURE MEDICINE 1997;3(6):632-8

The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region
Selivanova G, Iotsova V, Kiseleva E, Strom M, Bakalkin G, Grafstrom Rc, et al
NUCLEIC ACIDS RESEARCH 1996;24(18):3560-7

P53 - A CELL-CYCLE REGULATOR ACTIVATED BY DNA-DAMAGE
Selivanova G, Wiman Kg
ADVANCES IN CANCER RESEARCH, VOL 66 1995;:143-80

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
Selivanova G, Bakalkin G, Yakovleva T, Kiseleva E, Szekely L, Terenius L, et al
JOURNAL OF CELLULAR BIOCHEMISTRY 1995;:77-77

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
Selivanova G, Bakalkin G, Yakovleva T, Kiseleva E, Szekely L, Terenius L, et al
JOURNAL OF CELLULAR BIOCHEMISTRY 1995;:325-325

P53 BINDS SINGLE-STRANDED-DNA ENDS THROUGH THE C-TERMINAL DOMAIN AND INTERNAL DNA SEGMENTS VIA THE MIDDLE DOMAIN
Bakalkin G, Selivanova G, Yakovleva T, Kiseleva E, Kashuba E, Magnusson Kp, et al
NUCLEIC ACIDS RESEARCH 1995;23(3):362-9

RESTING B-CELLS, EBV-INFECTED B-BLASTS AND ESTABLISHED LYMPHOBLASTOID CELL-LINES DIFFER IN THEIR RB, P53 AND EBNA-5 EXPRESSION PATTERNS
Szekely L, Pokrovskaja K, Jiang Wq, Selivanova G, Lowbeer M, Ringertz N, et al
ONCOGENE 1995;10(9):1869-74

Visa alla publikationer